Scholarlink

Background <p>This study aimed to evaluate the impact of introducing faricimab into a publicly funded drug programme for retinal diseases, focusing particularly on reducing treatment frequency and optimising resources. Faricimab, a bispecific antibody targeting angiopoietin-2 and VEGF-A, offers a dual mechanism for managing nAMD and DME, both leading causes of vision loss.</p> Methods <p>The analysis included forecasting patient treatment trends, estimating the potential market share of faricimab, and simulating drug administration frequencies. A Monte Carlo simulation was conducted to model the impact of faricimab on reducing injection frequency. Scenarios with variable patient numbers and administration rates were explored, covering the years 2025, 2030, and 2035, to assess potential efficiencies in healthcare resources use and the capacity to treat additional patients.</p> Results <p>Results indicated that faricimab could reduce injection frequency by approximately 15%, freeing up resources within the healthcare system. Under the primary scenario, faricimab introduction could enable an additional 2,115 patients to be treated in 2025, rising to 7,662 by 2035 without additional resources. In the minimum scenario, the capacity increased by 4,415 patients by 2035, while the maximum scenario saw an increase of 12,003 patients.</p> Conclusions <p>The introduction of faricimab is expected to improve access to ophthalmic treatments, especially within the drug programme for retinal diseases, by decreasing injection frequency and enhancing resource efficiency. Given Poland’s ageing population and the rising prevalence of nAMD and DME, faricimab adoption could alleviate pressures on healthcare infrastructure, ultimately supporting better patient outcomes and overcoming current limitations in access to ophthalmic services.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Multidimensional evaluation of the potential impact of faricimab availability on healthcare system accessibility for retinal disease treatment in Poland

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月23日

查看全文
  • Michał Seweryn,
  • Justyna Kopel,
  • Joanna Augustynska,
  • Adam Mikołajewicz,
  • Mario Damiano Toro,
  • Robert Rejdak

摘要

Background

This study aimed to evaluate the impact of introducing faricimab into a publicly funded drug programme for retinal diseases, focusing particularly on reducing treatment frequency and optimising resources. Faricimab, a bispecific antibody targeting angiopoietin-2 and VEGF-A, offers a dual mechanism for managing nAMD and DME, both leading causes of vision loss.

Methods

The analysis included forecasting patient treatment trends, estimating the potential market share of faricimab, and simulating drug administration frequencies. A Monte Carlo simulation was conducted to model the impact of faricimab on reducing injection frequency. Scenarios with variable patient numbers and administration rates were explored, covering the years 2025, 2030, and 2035, to assess potential efficiencies in healthcare resources use and the capacity to treat additional patients.

Results

Results indicated that faricimab could reduce injection frequency by approximately 15%, freeing up resources within the healthcare system. Under the primary scenario, faricimab introduction could enable an additional 2,115 patients to be treated in 2025, rising to 7,662 by 2035 without additional resources. In the minimum scenario, the capacity increased by 4,415 patients by 2035, while the maximum scenario saw an increase of 12,003 patients.

Conclusions

The introduction of faricimab is expected to improve access to ophthalmic treatments, especially within the drug programme for retinal diseases, by decreasing injection frequency and enhancing resource efficiency. Given Poland’s ageing population and the rising prevalence of nAMD and DME, faricimab adoption could alleviate pressures on healthcare infrastructure, ultimately supporting better patient outcomes and overcoming current limitations in access to ophthalmic services.